NO152217C - Analogifremgangsmaate ved fremstilling av nye terapeutisk aktive 3-(1-imidazolylalkyl)indoler - Google Patents

Analogifremgangsmaate ved fremstilling av nye terapeutisk aktive 3-(1-imidazolylalkyl)indoler

Info

Publication number
NO152217C
NO152217C NO800650A NO800650A NO152217C NO 152217 C NO152217 C NO 152217C NO 800650 A NO800650 A NO 800650A NO 800650 A NO800650 A NO 800650A NO 152217 C NO152217 C NO 152217C
Authority
NO
Norway
Prior art keywords
imidazolylalkyl
indoles
preparation
new therapeutic
therapeutic active
Prior art date
Application number
NO800650A
Other languages
English (en)
Norwegian (no)
Other versions
NO800650L (no
NO152217B (no
Inventor
Peter Edward Cross
Roger Peter Dickinson
Original Assignee
Pfizer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer filed Critical Pfizer
Publication of NO800650L publication Critical patent/NO800650L/no
Publication of NO152217B publication Critical patent/NO152217B/no
Publication of NO152217C publication Critical patent/NO152217C/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/12—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/56—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
    • C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D249/08—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
NO800650A 1979-03-07 1980-03-06 Analogifremgangsmaate ved fremstilling av nye terapeutisk aktive 3-(1-imidazolylalkyl)indoler NO152217C (no)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GB7908123 1979-03-07

Publications (3)

Publication Number Publication Date
NO800650L NO800650L (no) 1980-09-08
NO152217B NO152217B (no) 1985-05-13
NO152217C true NO152217C (no) 1985-08-21

Family

ID=10503707

Family Applications (1)

Application Number Title Priority Date Filing Date
NO800650A NO152217C (no) 1979-03-07 1980-03-06 Analogifremgangsmaate ved fremstilling av nye terapeutisk aktive 3-(1-imidazolylalkyl)indoler

Country Status (36)

Country Link
US (1) US4273782A (da)
JP (1) JPS55133380A (da)
KR (1) KR850000760B1 (da)
AR (1) AR227015A1 (da)
AT (1) AT375366B (da)
AU (1) AU516957B2 (da)
BE (1) BE882113A (da)
CA (1) CA1120479A (da)
CH (1) CH649546A5 (da)
CS (1) CS253702B2 (da)
DD (1) DD149525A5 (da)
DE (1) DE3008632A1 (da)
DK (1) DK151884C (da)
ES (2) ES489220A0 (da)
FI (1) FI66860C (da)
FR (1) FR2450832A1 (da)
GR (1) GR67237B (da)
HK (1) HK89884A (da)
HU (1) HU184727B (da)
IE (1) IE49542B1 (da)
IL (1) IL59524A (da)
IT (1) IT1218420B (da)
KE (1) KE3467A (da)
LU (1) LU82224A1 (da)
MY (1) MY8500285A (da)
NL (1) NL182959C (da)
NO (1) NO152217C (da)
NZ (1) NZ193052A (da)
PH (1) PH15198A (da)
PL (1) PL128296B1 (da)
PT (1) PT70914A (da)
SE (1) SE440778B (da)
SG (1) SG67284G (da)
SU (1) SU1277894A3 (da)
YU (1) YU41911B (da)
ZA (1) ZA801328B (da)

Families Citing this family (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4414159A (en) * 1980-09-26 1983-11-08 E. I. Du Pont De Nemours & Co. Vinyl ether monomers and polymers therefrom
US4444775A (en) * 1981-06-22 1984-04-24 Ciba-Geigy Corporation Substituted imidazo[1,5-A]pyridines
KR840000529A (ko) * 1981-07-07 1984-02-25 콘스탄틴 루이스 클레멘트 인돌 유도체의 제조방법
ZA825413B (en) * 1981-08-26 1983-06-29 Pfizer Thromboxane synthetase inhibitors, processes for their production, and pharmaceutical compositions comprising them
US4478842A (en) * 1981-11-19 1984-10-23 Ciba-Geigy Corporation N-Substituted-2-pyridylindoles
US4460777A (en) * 1981-11-19 1984-07-17 Ciba-Geigy Corporation N-Substituted-2-pyridylindoles
US4436746A (en) 1982-09-30 1984-03-13 Ciba-Geigy Corporation Thromboxane synthetase inhibitory N-substituted-2-(1-imidazolyl)indoles
US4539410A (en) * 1982-09-30 1985-09-03 Ciba-Geigy Corporation N-Substituted-2-(1-imidazolyl)indoles
AT376436B (de) * 1982-11-05 1984-11-26 Laevosan Gmbh & Co Kg Verfahren zur herstellung neuer thiophen-2carbons[urederivate und pharmazeutisch vertraeglicher saeure- oder basenadditionssalze davon
US4511573A (en) * 1983-05-17 1985-04-16 Ciba-Geigy Corporation 3-Substituted-2-(heteroaryl) indoles
EP0239306B1 (en) 1986-03-27 1993-06-02 Merck Frosst Canada Inc. Tetrahydrocarbazole esters
JPH0832679B2 (ja) * 1986-09-05 1996-03-29 理化学研究所 Ｎ―フタルイシド誘導体及びその製造法
GR871809B (en) * 1986-11-28 1988-03-07 Glaxo Group Ltd Process for the preparation of tricyclic ketones
EP0427860A1 (en) * 1989-03-31 1991-05-22 Kyoto Pharmaceutical Industries, Ltd. New imidazole derivatives, production thereof, and uses thereof as medicines
DE4023215A1 (de) * 1990-07-21 1992-01-23 Hoechst Ag Substituierte azole, verfahren zu deren herstellung, sie enthaltende mittel und deren verwendung
AU642041B2 (en) * 1990-09-13 1993-10-07 Beecham Group Plc Indole ureas as 5 HT receptor antagonist
US5162337A (en) * 1990-10-05 1992-11-10 Merck & Co., Inc. Animal growth promotion
US5120749A (en) * 1991-02-20 1992-06-09 Abbott Laboratories Platelet activating antagonists
US5463074A (en) * 1991-12-18 1995-10-31 Schering Corporation Imidazolyl or imidazoylalkyl substituted with a four or five membered nitrogen containing heterocyclic ring
US5538973A (en) * 1992-03-27 1996-07-23 Kyoto Pharmaceutical Industries, Ltd. Imidazole derivative, pharmaceutical use thereof, and intermediate therefor
AU658729B2 (en) * 1992-03-27 1995-04-27 Kyoto Pharmaceutical Industries, Ltd. 3-(1H-imidazol-1-ylmethyl)-1H-indole derivatives
JPH0632913U (ja) * 1992-09-18 1994-04-28 三洋電機株式会社 床暖房用パネル
EE200000573A (et) * 1998-03-31 2002-04-15 The Institutes For Pharmaceutical Discovery, Llc Asendatud indoolalkaanhapped
EP1569899B1 (en) * 2002-12-10 2006-06-28 Wyeth Substituted 3-alkyl- and 3-arylalkyl-1h-indol-1-yl-acetic acid derivatives as inhibitors of plasminogen activator inhibitor-1 (pai-1)
GB0324763D0 (en) * 2003-10-23 2003-11-26 Oxagen Ltd Use of compounds in therapy
ATE499344T1 (de) * 2004-10-12 2011-03-15 Decode Genetics Ehf Peri-substituierte bicyclische sulfonamide gegen arterielle verschlusskrankheit
US7803828B2 (en) * 2005-08-25 2010-09-28 Schering-Plough Corporation Functionally selective alpha2C adrenoreceptor agonists
GB2431927B (en) * 2005-11-04 2010-03-17 Amira Pharmaceuticals Inc 5-Lipoxygenase-activating protein (FLAP) inhibitors
US7977359B2 (en) 2005-11-04 2011-07-12 Amira Pharmaceuticals, Inc. 5-lipdxygenase-activating protein (FLAP) inhibitors
US8399666B2 (en) * 2005-11-04 2013-03-19 Panmira Pharmaceuticals, Llc 5-lipoxygenase-activating protein (FLAP) inhibitors
CN101490045A (zh) * 2006-05-16 2009-07-22 解码遗传Ehf公司 7-(丙烯酰基)吲哚的制备方法
JP5270542B2 (ja) 2006-07-22 2013-08-21 オキサジェン リミテッド Ｃｒｔｈ２アンタゴニスト活性を有する化合物
TW200920369A (en) * 2007-10-26 2009-05-16 Amira Pharmaceuticals Inc 5-lipoxygenase activating protein (flap) inhibitor
US20110015158A1 (en) 2007-12-11 2011-01-20 Viamet Pharmaceuticals, Inc. Metalloenzyme inhibitors using metal binding moieties in combination with targeting moieties
US7750027B2 (en) 2008-01-18 2010-07-06 Oxagen Limited Compounds having CRTH2 antagonist activity
DK2250161T3 (da) 2008-01-18 2014-01-27 Atopix Therapeutics Ltd Forbindelser med CRTH2-antagonistaktivitet
WO2009093029A1 (en) * 2008-01-22 2009-07-30 Oxagen Limited Compounds having crth2 antagonist activity
US20100022613A1 (en) * 2008-01-22 2010-01-28 Oxagen Limited Compounds Having CRTH2 Antagonist Activity
CN102137858B (zh) * 2008-05-23 2014-07-23 潘米拉制药有限责任公司 5-脂氧合酶-活化蛋白抑制剂
US8546431B2 (en) 2008-10-01 2013-10-01 Panmira Pharmaceuticals, Llc 5-lipoxygenase-activating protein (FLAP) inhibitors
CA2877474A1 (en) * 2011-06-20 2012-12-27 Myrexis, Inc. Compounds and therapeutic uses thereof
GB201322273D0 (en) 2013-12-17 2014-01-29 Atopix Therapeutics Ltd Process
GB201407820D0 (en) 2014-05-02 2014-06-18 Atopix Therapeutics Ltd Polymorphic form
GB201407807D0 (en) 2014-05-02 2014-06-18 Atopix Therapeutics Ltd Polymorphic form
US11530186B2 (en) * 2018-03-29 2022-12-20 H. Lee Moffitt Cancer Center and Research Center Institute, Inc. Inhibitors for the β-catenin / T-cell factor protein-protein interaction

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL125443C (da) * 1963-06-06
US3370063A (en) * 1964-10-05 1968-02-20 Mcneilab Inc Substituted dimethoxy indoles and method of making the same
US3621027A (en) * 1968-03-18 1971-11-16 Endo Lab 1-aminoalkyl-2,6-diaryl 4,5,6,7 tetrahydro-4-oxindales
US3931229A (en) * 1973-08-23 1976-01-06 Warner-Lambert Company 3-Thiomethyl-2[2-(dialkylamino)ethyl]indoles
US4059583A (en) * 1975-11-13 1977-11-22 Mcneil Laboratories, Incorporated Substituted indoles
DK376078A (da) * 1977-08-26 1979-02-27 Wellcome Found Fremgangsmaade til fremstilling af amidazoler
US4140858A (en) * 1977-12-19 1979-02-20 Warner-Lambert Company 3-(1H-imidazol-1-ylmethyl)-2-(disubstitutedaminomethyl)indoles and a method for their production
DE2960547D1 (en) * 1978-02-24 1981-11-05 Pfizer Ltd 3-(imidazol-1-ylalkyl)indoles as selective inhibitors of thromboxane synthetase,pharmaceutical compositions thereof, and methods for preparing them

Also Published As

Publication number Publication date
SG67284G (en) 1985-03-15
AR227015A1 (es) 1982-09-15
PL222470A1 (da) 1980-12-01
IE49542B1 (en) 1985-10-30
DK151884C (da) 1988-06-13
IT8020399A0 (it) 1980-03-06
LU82224A1 (fr) 1980-06-06
IT1218420B (it) 1990-04-19
AT375366B (de) 1984-07-25
ATA125780A (de) 1983-12-15
NZ193052A (en) 1984-07-06
ZA801328B (en) 1981-03-25
NL182959C (nl) 1988-06-16
SU1277894A3 (ru) 1986-12-15
FI800672A (fi) 1980-09-08
DK151884B (da) 1988-01-11
PT70914A (en) 1980-04-01
SE8001736L (sv) 1980-09-08
GR67237B (da) 1981-06-25
YU61480A (en) 1983-12-31
KE3467A (en) 1984-11-09
HK89884A (en) 1984-11-23
CS253702B2 (en) 1987-12-17
SE440778B (sv) 1985-08-19
AU5623180A (en) 1980-09-11
AU516957B2 (en) 1981-07-02
CA1120479A (en) 1982-03-23
HU184727B (en) 1984-10-29
PH15198A (en) 1982-09-17
FR2450832B1 (da) 1983-04-22
ES496889A0 (es) 1982-08-01
CH649546A5 (de) 1985-05-31
ES8205789A1 (es) 1982-08-01
NO800650L (no) 1980-09-08
ES8104278A1 (es) 1981-04-01
DD149525A5 (de) 1981-07-15
DE3008632A1 (de) 1980-10-16
ES489220A0 (es) 1981-04-01
KR830001928A (ko) 1983-05-19
US4273782A (en) 1981-06-16
DK42580A (da) 1980-09-08
JPS55133380A (en) 1980-10-17
FI66860B (fi) 1984-08-31
NL8001351A (nl) 1980-09-09
BE882113A (fr) 1980-09-08
IL59524A0 (en) 1980-06-30
NO152217B (no) 1985-05-13
IE800453L (en) 1980-09-07
FI66860C (fi) 1984-12-10
PL128296B1 (en) 1984-01-31
MY8500285A (en) 1985-12-31
YU41911B (en) 1988-02-29
KR850000760B1 (ko) 1985-05-25
JPS6141513B2 (da) 1986-09-16
DE3008632C2 (da) 1988-02-25
FR2450832A1 (fr) 1980-10-03
IL59524A (en) 1982-11-30

Similar Documents

Publication Publication Date Title
NO152217C (no) Analogifremgangsmaate ved fremstilling av nye terapeutisk aktive 3-(1-imidazolylalkyl)indoler
NO151085C (no) Analogifremgangsmaate ved fremstilling av nye, terapeutisk aktive peptidylargininaldehydderivater
NO147148C (no) Analogifremgangsmaate ved fremstilling av nye terapeutisk aktive fenyletanolaminderivater
NO153136C (no) Analogifremgangsmaate ved fremstilling av nye terapeutisk aktive naftyridinderivater.
NO149962C (no) Analogifremgangsmaate ved fremstilling av terapeutisk aktive imidazolderivater
NO800858L (no) Analogifremgangsmaate ved fremstilling av terapeutisk aktive 4-amino-3-kinolincarboxylsyrederivater
NO151321C (no) Analogifremgangsmaate for fremstilling av terapeutisk aktive karbostyrilderivater
NO803868L (no) Fremgangsmaate ved fremstilling av nye kinazolinderivater
NO151463C (no) Analogifremgangsmaate for fremstilling av terapeutisk aktive kinazolinderivater
NO152841C (no) Analogifremgangsmaate ved fremstilling av terapeutisk aktive nye 4-aroylimidazol-2-oner.
NO153135C (no) Analogifremgangsmaate ved fremstilling av terapeutisk virksomme n-(fenoksyalkyl)-imidazolderivater.
NO800881L (no) Analogifremgangsmaate for fremstilling av terapeutisk aktive kinolonderivater
NO151702C (no) Analogifremgangsmaate ved fremstilling av terapeutisk aktive substituerte acetofenoner
NO149312C (no) Analogifremgangsmaate ved fremstilling av terapeutisk aktivt 2-(2-tenoyltio)-propionylglycin
NO146392C (no) Analogifremgangsmaate ved fremstilling av nye analgesisk aktive n-acetyl-para-aminofenyl-n`-acetyl-aminoalkansyreester-derivater
NO154426C (no) Analogifremgangsmaate ved fremstilling av nye terapeutisk aktive trans-3-(4-okso-4h-kinazolin-3-yl)-2-propensyrederivater.
NO149210C (no) Analogifremgangsmaate ved fremstilling av terapeutisk aktive 3-(1-pyrazolyl)-pyridazinderivater
NO145791C (no) Analogifremgangsmaate ved fremstilling av nye terapeutisk aktive imidazolderivater
NO148642C (no) Analogifremgangsmaate ved fremstilling av terapeutisk aktive, nye prostacyclinderivater
NO146359C (no) Analogifremgangsmaate ved fremstilling av terapeutisk aktive cyproheptadinderivater
NO151239C (no) Analogifremgangsmaate for fremstilling av terapeutisk aktive 2-fenyliminoimidazolidiner
NO150158C (no) Analogifremgangsmaate ved fremstilling av terapeutisk aktive 6,7-dimetoksyquinazolinderivater
NO153055C (no) Analogifremgangsmaate for fremstilling av terapeutisk aktive nye derivater av 2-(2-pyridyl)tetrahydrotiofen
NO149964C (no) Analogifremgangsmaate ved fremstilling av terapeutisk aktive 3-(tetrazol-5-yl)-1-azaxanthoner
NO152172C (no) Analogifremgangsmaate for fremstilling av terapeutisk aktive spiro-kinolyl-hydantoin-derivater